Keywords: Piramal, Bayer, Molecular imaging portfolio, Florbetaben

Piramal buys molecular imaging portfolio from Bayer

Article | 16 April 2012

Print This

Indian drugmaker Piramal Healthcare (BSE: 500302) says it has signed an agreement to acquire worldwide rights to the molecular imaging R& ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in